Organon & Co.

Income statement revenue $1.56B (-2.3% YoY).Pre-tax income $183M (-20.1% YoY).Pre-tax result $183M (-20.1% YoY).Net result $108M (-25.5% YoY).

• Arcoxia: $69M (+9.5% YoY)
• Atozet: $80M (-7.0% YoY)
• Bildvos Bilprevda: $19M
• Brenzys: $14M (-36.4% YoY)
• Clarinex: $30M (-11.8% YoY)
• Cozaar Hyzaar: $50M (-10.7% YoY)
• Diprospan: $44M (+7.3% YoY)
• Dulera: $41M (+0.0% YoY)
• Emgality Ravvow: $54M (+28.6% YoY)
• Follistim AQ: $59M (-20.3% YoY)
• Fosamax: $25M (-26.5% YoY)
• Ganirelix Acetate Injection: $26M (-3.7% YoY)
• Hadlima: $79M (+58.0% YoY)
• Marvelon Mercilon: $32M (-3.0% YoY)
• Nasonex: $58M (-12.1% YoY)
• Nexplanon Implanon NXT: $230M (-4.2% YoY)
• Nuva Ring: $27M (-3.6% YoY)
• Ontruzant: $6M (-80.6% YoY)
• Other Biosimilars: $12M (+71.4% YoY)
• Other Cardiovascular: $25M (-26.5% YoY)
• Other Non Opiod Pain Bone And Dermatology: $79M (-1.3% YoY)
• Other Respiratory: $18M (+28.6% YoY)
• Other Sundry Established Brands: $96M (+10.3% YoY)
• Other Sundry Products: $14M (-39.1% YoY)
• Other Womens Health: $45M (+7.1% YoY)
• Propecia: $36M (+12.5% YoY)
• Proscar: $20M (-9.1% YoY)
• Renflexis: $65M (+3.2% YoY)
• Rosuzet: $5M (-16.7% YoY)
• Singulair: $48M (-27.3% YoY)
• Vtama: $35M (+12.9% YoY)
• Vytorin: $21M (-22.2% YoY)
• Zetia: $96M (+29.7% YoY)
• Costs and expenses: $664M (+2.9% YoY)
• Income tax expense: $75M (-10.7% YoY)